Serodus news update

December 20, 2018:

As mentioned in the 3rd quarterly report of 2018, Serodus is preparing for a private investment round among all shareholders. The financing will enable the company to initiate the next development stages of SER150 and SER140. 

Further information can be found in the enclosed presentation.

Eva Steiness, CEO

Serodus ASA

Serodus December 2018 presentation

Serodus ASA increases its share capital as a result of exercise of share options

Oslo, Norway, 6 December, 2018 –  Serodus ASA today announced that it has decided to increase its share capital by NOK 292.500 as a consequence of the exercise of a share option program from 2016.

Eva Steiness, CEO, has exercised her right to convert 225.000 options into shares. The shares are subscribed in cash at a price per share of NOK 1.30. Proceeds to the company are NOK 292.500. The increase in shares corresponds to approximately 0.3% of the company’s share capital. The new shares are ordinary shares without any special rights and are freely transferable negotiable instruments.   

Serodus ASA contact:

Eva Steiness, CEO

e-mail: eva.steiness@serodus.com

Trinity Delta 2018 Outlook Report

Trinity Delta Outlook Report 2018

Serodus remains on the cusp of a major inflection point, as it looks to leverage promising Phase IIa data for its lead asset, SER150 in diabetic nephropathy. The company is seeking new funds to progress its pipeline of five programmes, in addition to securing a licensing deal for SER150, an asset with blockbuster potential. Following the FDA Pre-IND meeting in September 2017, Serodus is on track to file an IND application for SER150 in H218 and expects to request Breakthrough Therapy Designation (BTD). FDA grant of BTD would clarify the regulatory pathway, shortening and facilitating SER150’s route to market, and may catalyse investment and/or a partnership.